- Conditions
- Nonconvulsive Electrographic Seizures
- Interventions
- Brivaracetam intravenous solution, Brivaracetam oral tablets, Phenytoin intravenous solution, Phenytoin oral tablets
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Jackson, Mississippi
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 55
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Epilepsy
- Interventions
- Brivaracetam (ucb34714)
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Charlottesville, Virginia • Madison, Wisconsin
- Conditions
- Sarcoma, Ewing, Sarcoma
- Interventions
- Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
- Drug
- Lead sponsor
- Sarcoma Oncology Research Center, LLC
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Tuberous Sclerosis Complex-associated Refractory Seizures
- Interventions
- RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Phenytoin Toxicity
- Interventions
- Activated Charcoal
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Adverse Drug Reaction
- Interventions
- Pharmacogenetic Intervention Arm (pharmacogenetic testing)
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
- Interventions
- Oral Topotecan and Temodar
- Drug
- Lead sponsor
- Katy Peters
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Healthy
- Interventions
- Poziotinib, Itraconazole, Phenytoin, Paroxetine
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
- Drug
- Lead sponsor
- Pancreatic Cancer Action Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Cognitive Measures, Driving Simulator Performance
- Interventions
- Phenytoin, Placebo oral capsule
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 25 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Temodar, O6-BG, and Irinotecan
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Healthy
- Interventions
- Extended Phenytoin Sodium Capsules 100 mg, Dilantin® Kapseals® 100 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Not Determined
- Interventions
- Phenytoin, Itraconazole, sonrotoclax
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
- Interventions
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma
- Interventions
- Temodar and SCH 66336
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Epilepsy, Seizure, Cognition Disorders
- Interventions
- Differential Abilities Scale, Neuropsychological Testing
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- Female only
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
- Conditions
- Cognitive Impairment
- Interventions
- Phenytoin 200 mg capsule, Megestrol 800 mg liquid, Phenytoin-matched Placebo capsule, Megestrol-matched liquid Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
- Interventions
- Campath -1H, Dilantin, Busulfan, Cyclophosphamide
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Day to 64 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Renal Failure, Pharmacokinetics
- Interventions
- Levetiracetam, Lacosamide, Phenytoin, Phenobarbital, Ketamine, Valproic Acid
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Participants
- Interventions
- BMS-986166, Itraconazole, Extended Phenytoin Sodium, Gemfibrozil
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Berlin, New Jersey
- Conditions
- Tonic-clonic Seizure
- Interventions
- Keppra, Fosphenytoin, Dilantin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Epilepsy
- Interventions
- Oxcarbazepine (brand name vs generic drugs), Divalproex Sodium (brand name vs generic drugs), Carbamazepine (brand name vs generic drugs), Lamotrigine (brand name vs generic drugs), levetiracetam (brand name vs generic drugs), Topiramate (brand name vs generic drugs), Zonisamide (brand name vs generic drugs), Phenytoin sodium (brand name vs generic drugs)
- Drug
- Lead sponsor
- Food and Drug Administration (FDA)
- Federal
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- terameprocol, pharmacological study
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Healthy
- Interventions
- Phenytoin (brand name Dilantin), Hydrocortisone, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas